Impact of ten-valent pneumococcal conjugate vaccine on pneumonia in Finnish children in a nation-wide population-based study by Palmu, Arto A et al.
RESEARCH ARTICLE
Impact of ten-valent pneumococcal conjugate
vaccine on pneumonia in Finnish children in a
nation-wide population-based study
Arto A. Palmu1*, Hanna Rinta-Kokko2, Hanna Nohynek3, J. Pekka Nuorti3, Terhi M. Kilpi2,
Jukka Jokinen2
1 Department of Public Health Solutions, National Institute for Health and Welfare, Tampere, Finland,
2 Department of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland,
3 Department of Health Security, National Institute for Health and Welfare, Helsinki, Finland
* arto.palmu@thl.fi
Abstract
Background
The ten-valent pneumococcal conjugate vaccine (PCV10) was introduced into the Finnish
National Vaccination Program (NVP) in September 2010 using a 2+1 schedule (3, 5, 12
months). We estimated the direct and indirect effects of PCV10 on pneumonia among chil-
dren to evaluate the public health impact of the vaccine.
Methods
We conducted a nation-wide population-based, observational study comparing rates of
pneumonia in children before and after the NVP introduction. For the total (direct and indi-
rect) effect, the cohort of vaccine-eligible children (born June 1, 2010 or later) was followed
until the end of 2013 (age range 3–42 months). For the indirect effect, a cohort of older chil-
dren (age range 7–71 months) not eligible for the PCV vaccination was followed from 2011
to 2013. Both cohorts were compared with two season- and age-matched reference cohorts
before NVP introduction. Hospitals’ in- and outpatient discharge notifications with ICD-10
diagnoses compatible with pneumonia (J10.0, J11.0, J12-J18, J85.1 or J86) as set by the
hospital pediatricians were collected from the national Care Register. The main outcome
was hospital-treated primary pneumonia (HTPP), defined as primary diagnosis of pneumo-
nia after in-patient hospitalization. We compared rates of pneumonia in the NVP target and
reference cohorts by using Poisson regression models.
Results
The rate of HTPP episodes was 5.3/1000 person-years in the combined reference cohorts
and 4.1/1000 person-years in the target cohort vaccine-eligible children. Compared with the
reference cohort, the relative rate reduction in target cohort was 23% (95%CI 18–28) and
the absolute reduction 1.3/1000 person-years. In the indirect effect evaluation, we observed
continued increase in HTPP incidence until 2011 with a subsequent reduction of 18% (95%
CI 10–25) during years 2012 to 2013. Number of empyema diagnoses remained low.
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Conclusions
A substantial decrease in pneumonia rates was observed both among vaccine-eligible chil-
dren and among older, unvaccinated children after PCV10 introduction.
Introduction
Pneumonia is the number one killer in low-income countries in children below 5 years of age
[1]. In affluent countries the mortality is low, yet high disease burden remains. Streptococcus
pneumoniae (pneumococcus) has been considered as the most common etiology in commu-
nity-acquired pneumonia in children [2]. Pneumococcal conjugate vaccines have been devel-
oped to reduce this disease burden. Currently, two PCVs, 10-valent PHiD-CV10 (PCV10,
GlaxoSmithKline, Belgium) and 13-valent PnCRM (PCV13, Pfizer, USA) licensed in 2009 are
now being widely used throughout the world, both in affluent and low-income countries.
PCVs have been previously shown to reduce pneumonia in children. In randomized clinical
trials PCV7 [3–4], PCV9 [5–6], and PCV10 [7–8] reduced both clinical and radiological pneu-
monia, but PCV11 only radiological pneumonia [9]. No RCTs for pneumonia have been per-
formed in children with PCV13, which is a successor of the PCV7.
Reduction in pneumonia hospital admissions in children has been observed in many coun-
tries after large-scale introduction of the PCVs in infant vaccination programmes [10–16],
although also negative results have been published [17]. There are also reports suggesting indi-
rect impact on all-cause pneumonia for PCV7 in young adults [10] and also in longer term in
older age groups as well [18], and for PCV13 [19] but to our knowledge there is no evidence of
impact for PCV10 yet.
After a public tender, PCV10 was introduced into the Finnish National Vaccination Pro-
gram (NVP) Program in September 2010. All children born June 1st, 2010 or later have been
eligible for vaccination with a 2+1 schedule (vaccinations at 3, 5, and 12 months of age) with-
out catch-up vaccinations for older age cohorts. We used the Finnish hospital discharge regis-
ter data to explore the public health impact of the PCV10-NVP on pneumonia in the target
group of vaccine-eligible children and also in older unvaccinated children for the indirect
effect.
Methods
We used a population-based, nation-wide observational study design as described previously
[20].
For total (direct and indirect) effects, we compared pneumonia rates in the vaccine-eligible
cohort during the vaccination program to season- and age-matched reference cohorts before
vaccine introduction (Fig 1).
For indirect effects, we compared pneumonia rates in a cohort of older children not eligible
for vaccination during the vaccination program with season- and age-matched reference
cohorts before vaccine introduction (Fig 2).
Vaccination program
The NVP vaccines purchased by the government are administered at the local municipal well-
baby clinics free of charge. The PCV10 vaccination coverage for children born during the cal-
endar year 2012 was estimated in a recent survey to be 93% for the first dose and 92% for the
full series of three doses [21].
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Before PCV10 introduction into the NVP in 2010, use of PCVs in Finland was minimal and
mostly limited to a small group of children with specific high risk conditions for whom PCV7
was recommended during 2001–2010. On the basis of national sales figures (doses distrib-
uted), the estimated uptake of PCV among children <2 years of age was less than 2% until
2009. However, a large cluster-randomized PCV10 effectiveness trial (FinIP) was conducted in
Finland in 2009–2010 [22] in which more than 30,000 children under two years of age received
PCV10 vaccination (approximately 22% of the corresponding birth cohort).
Influenza vaccinations were included in the Finnish NVP in fall 2007 for children 6 to 36
months of age. The annual vaccine uptake was nearly 40% until fall 2009, but considerably
lower during the subsequent PCV10 era (<20%). However, during the season 2009 to 2010 the
use pandemic influenza A (H1N1) vaccine uptake was considerably higher, up to 70% in chil-
dren under five.
Outcome data collection and definitions
All hospital outpatient visits and inpatient hospitalizations in Finland are registered in the
Care Register for Health Care, a national hospital discharge register maintained by THL.
All hospitalizations and visits to hospitals associated with ICD-10 diagnoses compatible
with pneumonia (J10.0, J11.0, J12 to J18, J85.1 or J86, Table 1) were identified from the Care
Register. These cases were defined as hospital-diagnosed pneumonia (HDP). The main out-
come was hospital-treated primary pneumonia (HTPP), i.e. a case with a primary discharge
diagnosis of pneumonia after in-patient hospitalization. We also evaluated any Hospital-diag-
nosed pneumococcal pneumonia defined as any register-based event with an ICD10 diagnosis
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Fig 1. Cohorts for comparing the impact of PCV10 in vaccine-eligible children.
doi:10.1371/journal.pone.0172690.g001
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Fig 2. Cohorts for comparing the indirect effect of PCV10 in unvaccinated children.
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Table 1. ICD-10 codes compatible with pneumonia and their distribution in the two reference cohorts
from 2003 to 2006 and 2005 to 2008.
ICD-10
code
Diagnosis in text Proportion of episodes in the reference
cohorts, %
J10.0 Influenza with pneumonia, virus identified 1.1
J11.0 Influenza with pneumonia, virus not
identified
0.4
J12 Viral pneumonia 7.9
J13 Pneumonia due to Streptococcus
pneumoniae
2.5
J14 Pneumonia due to Haemophilus
influenzae
0
J15 Bacterial pneumonia, not elsewhere
classified
20.0
J16 Pneumonia due to other infectious
organisms
0.1
J17 Pneumonia in diseases classified
elsewhere
0.1
J18 Pneumonia, organism unspecified 67.5
J85.1 Abscess of lung with pneumonia 0.1
J86 Pyothorax, including empyema 0.3
doi:10.1371/journal.pone.0172690.t001
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compatible with pneumococcal pneumonia (ICD-10 code J13); and Empyema defined as
ICD10 code J86 and hospitalization at least overnight.
No radiological data were available for evaluation of the pneumonia cases. No results of any
diagnostic tests performed in the hospital were available. However, pneumonia cases were
linked with the blood culture confirmed cases reported to the National Infectious Diseases
Register to detect cases of bacteremic pneumonia.
We used a 90-day period starting from the first pneumonia event to combine potential mul-
tiple events into one episode.
Cohorts and follow-up for assessment of total (direct and indirect) effects
To compare pneumonia rates before and after NVP introduction we constructed PCV10 target
and reference cohorts by using the data from the Population Information System as previously
reported [20].
Vaccine-eligible children were defined as those with birthdates from June 2010 to Septem-
ber 2013 (PCV10 target cohort, Fig 1) irrespective of whether they had received the vaccine or
not. For the assessment of total effects of PCV10, two age- and season-matched reference
cohorts were formed of children born June 2003—September 2006 (Reference cohort 1, Fig 1),
and June 2005—September 2008 (Reference cohort 2, Fig 1). In each of the cohorts, follow-up
started at three months of age (i.e., the expected age at the first dose) and ended between the
ages of 3 to 42 months.
To minimize the influence of the FinIP trial vaccinations [22] in the reference cohorts, the
cohorts were formed in such a way that the years 2009–2010 were not included in the follow
up (Fig 1).
Cohorts and follow-up for assessment of indirect effects
For the evaluation of indirect PCV10 effects, the unvaccinated cohort of children included
those born from January 2008 through May 2010 (target cohort for indirect effects, Fig 2).
Children vaccinated with PCV10 in the cluster-randomized PCV10 effectiveness trial [22]
were excluded. For the comparison, two age and season matched reference cohorts were
formed that included children born from January 2001 through May 2003, and from January
2003 through May 2005 (Fig 2) with follow-up between 7 to 71 months of age.
For the analysis, the follow-up time was divided into two periods to assess the development
of the indirect effect after PCV10 introduction. In the target cohort, the first period included
year 2011 and the second period years 2012 to 2013 (Fig 2). These time periods were compared
with the age- and season-matched time periods in the two reference cohorts (Fig 2).
Year 2014 data were included in the descriptive analyses for both vaccinated and unvacci-
nated populations.
Statistical analysis
Pneumonia rates in the target cohort were compared to rates in the combined reference
cohorts using Poisson regression models. Numbers of pneumonia cases in the cohorts during
the observation periods were tabulated and the corresponding person-years of follow-up were
used as weights in the analysis. Relative rate reduction (percent) was calculated as (1 –relative
risk)100%. In case of zero cases in either cohorts, ratio of Poisson means was derived condi-
tional on total number of cases [23] and Clopper-Pearson confidence interval for the resulting
binomial distribution was used [24]. Absolute rate reductions and the corresponding 95% con-
fidence intervals were calculated from the model estimates using the delta method.
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The study protocol was approved by the THL institutional review board. Permission to use
the register data were obtained from the relevant register controllers at THL.
Results
The incidence of pneumonia showed marked seasonal fluctuation, peaks occurring in late fall,
winter, or early spring months from October through March, varying in magnitude and tim-
ing each year (Fig 3). To reduce the effect of this variation on annual estimates yearly rates
were calculated by epidemic years (July to June). From 2003/2004 through 2009/2010 the inci-
dence of hospital-diagnosed pneumonia fluctuated considerably and increased in children <5
years of age (Figs 4 and 5). After the PCV introduction, pneumonia rates decreased substan-
tially in 2012 to 2014 (Figs 4 and 5), but empyema rates remained stable.
Total (direct and indirect) impact of PCV10 in children
The analysis included 334 087 child-years of follow-up in the target cohort eligible for vaccina-
tion; the rate of any pneumonia (HDP) episodes was 9.0/1000 person-years compared with
10.3/1000 person-years in the combined reference cohorts (relative rate reduction 13% (95%
CI 9–16); absolute rate reduction 1.3/1000 person-years, Table 2).
For HTPP, the incidences were roughly half of HDP with the relative rate reduction of 23%
(95%CI 18–28) in the vaccine-eligible cohort compared to the reference cohorts and a similar
absolute rate reduction as for any HDP. The incidence of HTPP by age is shown in Fig 6. The
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Fig 3. Monthly incidence rates of pneumonia in children <24 months of age from 2000 through end 2014 with vertical
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incidence was lower in the target cohort in all age groups from 6–8 months of age (i.e. after
two doses) through 39–42 months of age.
There were 5 cases of empyema in both of the two reference cohorts (0.2% of all pneumonia
cases). After NVP introduction, similar incidence with 5 cases was observed also in the target
cohort eligible for vaccination; relative rate reduction was 3% (95%CI -174 to 70).
Vaccine-type bacteremic pneumonia was recorded only in 5 children in the target cohort.
The relative rate reduction was 87% (95% CI 72 to 96, Table 2).
Indirect PCV10 effects in unvaccinated children
The pneumonia rates/1,000 person-years for the follow-up year 2011 and 2012/2013 combined
are presented in Table 3.
There was no reduction observed in calendar year 2011 in unvaccinated children 7–48
months of age. However, in 2012 and 2013 combined, there was a statistically significant
reduction of 18% in hospital-treated primary pneumonia and 70% in pneumococcal pneumo-
nia in unvaccinated children 19–71 months of age. This reduction was especially prominent in
children below 4 years of age with reversal of the increasing trend (S1 Fig).
Discussion
We observed an increasing trend in register-based pneumonia episodes before the PCV10
introduction into the Finnish National Vaccination Programme followed by a significant
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Table 2. Rates of pneumonia and the corresponding rate reductions in PCV10 eligible target cohort vs. reference cohorts.
Incidence rate
/1000 in reference
cohorts (No. of
cases)
Incidence rate /1000 in target
cohort (No. of cases)
Relative rate reduction
(95% CI)
Absolute rate reduction
(95% CI)
2003–
061
2005–081 2010–20132 Target vs. reference
cohorts combined
Target vs. reference
cohorts combined
Hospital-diagnosed pneumonia 9.8
(3141)
10.8
(3549)
9.0 (3004) 13 (9, 16) 1.3 (0.9, 1.7)
Hospital-treated primary
pneumonia
5.1
(1626)
5.6
(1838)
4.1 (1364) 23 (18, 28) 1.3 (1.0, 1.5)
Hospital-diagnosed
pneumococcal pneumonia
0.23
(73)
0.27 (88) 0.06 (19) 77 (64, 86) 0.2 (0.1, 0.2)
Empyema 0.016
(5)
0.015 (5) 0.015 (5) 3 (-174, 70) 0.0 (-0.02, 0.02)
Vaccine-type bacteremic
pneumonia
0.12
(38)
0.12 (39) 0.015 (5) 87 (72, 96) 0.1 (0.07, 0.13)
1) Follow-up years in the two reference cohorts 649,877, age 3–42 months, born Jun’03-Sep’06 or Jun’05-Sep’08.
2) Follow-up years in the target cohort 334,087, age 3–42 months, born Jun’10-Sep’13.
doi:10.1371/journal.pone.0172690.t002
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decrease after it. Similar trends were seen for both the vaccinated and unvaccinated popula-
tions. No increase in empyema rates was detected in the follow-up until end 2014; however,
the number of cases was low.
In clinical trials with PCV7, PCV9, PCV10, and PCV11 the VE estimates in the reduction
of clinical pneumonia have ranged from -1 to 17% [3–7, 9]. However, the study population,
outcome detection methods, case definitions and vaccination schedules differ from trial to
trial. A higher point estimate of 27% was observed in the FinIP trial conducted in Finland just
prior to the introduction of PCV into the NVP [8]. Furthermore, identical case definitions and
detection methods were used in the FinIP trial and the current study. The results are concor-
dant, yet the reduction in hospital-diagnosed pneumonia was lower in the current study com-
pared to the trial. This may be due to increasing trend in pneumonia diagnoses observed prior
to NVP implementation.
Our estimates are compatible with observational studies from Brazil [12, 25–26] and Chile
[16] after introduction of PCV10 as the first PCV, although in these countries the vaccine was
introduced with a 3+1 schedule. However, also much higher reductions in clinical pneumonia
have been reported in before-after studies ranging from 13% to up to 78% [10–11, 27–29].
0−
2 
m
o
3−
5 
m
o
6−
8 
m
o
9−
11
 m
o
12
−1
4 
m
o
15
−1
7 
m
o
18
−2
0 
m
o
21
−2
3 
m
o
24
−2
6 
m
o
27
−2
9 
m
o
30
−3
2 
m
o
33
−3
5 
m
o
36
−3
8 
m
o
>
=
39
 m
o
 
In
ci
de
nc
e/
10
00
 p
er
so
n 
ye
a
rs
0
2
4
6
8
10
Age in months
Reference cohort 1, follow−up 2003−2006
Reference cohort 2, follow−up 2005−2008
Target cohort, follow−up 2010−2013
Fig 6. The incidence of hospital-treated primary pneumonia (HTPP) by age in vaccine-eligible target
cohort compared to reference cohorts before introduction.
doi:10.1371/journal.pone.0172690.g006
Impact of pneumococcal conjugate vaccine on pneumonia
PLOS ONE | DOI:10.1371/journal.pone.0172690 March 1, 2017 9 / 14
Although higher reductions in national vaccination programmes with high vaccination cover-
age can be obtained than in clinical trials (due to the development of additional indirect
impact), it is difficult to foresee, how most of the clinical pneumonia could be prevented with
the current PCVs. The maximum expected reduction in overall clinical pneumonia might be
32% (assuming 50% of pneumonia caused by pneumococcus, 85% vaccine-type (+vaccine-
related type) coverage based on invasive pneumococcal disease data [20] since no data on
pneumonia are available, VE 85% against vaccine-type pneumonia, and modest 50% increase
in non-vaccine-type pneumococcal pneumonia, i.e. replacement disease, see S1 Table). Any
observation above that would most likely be biased due to other factors than vaccine impact.
Naturally, more specific outcomes for pneumococcal disease like consolidated pneumonia
would result in higher relative reductions and more sensitive outcomes like any clinical pneu-
monia including primary care diagnoses would result in lower estimates.
Looking at S1 Table in another way, the current relative and absolute reduction estimates
for HDP would be expected with following assumptions using invasive pneumococcal disease
as a reference [20](28% of pneumonia caused by pneumococcus, 81% vaccine-type coverage,
VE 70% against vaccine-type pneumonia, and 85% increase in non-vaccine-type pneumonia).
Different scenarios and examples from the current study are shown in S1 Table.
In addition to the well-known seasonal fluctuation in pneumonia due to viral epidemics,
there were also considerable year-to-year fluctuations of the pneumonia incidences. Upon
exploration of the National Infectious Diseases Register data [30] for various respiratory tract
pathogens during these calendar years for children under 5 years of age, influenza showed
highest peaks in 2003 and 2009, respiratory syncytial virus (RSV) in 2005, 2010, and 2014,
Table 3. Rates of pneumonia and the corresponding rate reductions in unvaccinated study cohort vs. reference cohorts.
Incidence rate/1000 in
reference cohorts (No.
of cases)
Incidence rate
/1000 in target
cohort (No. of
cases)
Relative rate reduction for
the indirect effect (95% CI)
Absolute rate reduction for
the indirect effect (95% CI)
Post
introduction
year
2004&20061 2005–06&
2007–082
20113 2012–
20134
2011 vs.
2004&2006
2012–13 vs.
2005–06 &
2007–08
2011 vs.
2004&2006
2012–13 vs.
2005–06 &
2007–08
Hospital-diagnosed
pneumonia
Year one 8.1 (1007
+1242)
11.9
(1452)
-46 (-56, -36) -3.7 (-4.4,
-3.0)
Years 2–3 6.3 (1600
+1878)
6.3
(1561)
-1 (-7, 5) -0.1 (-0.4,
0.3)
Hospital-treated
primary pneumonia
Year one 4.4 (536
+669)
5.5
(669)
-25 (-38, -14) -1.1 (-1.6,
-0.6)
Years 2–3 3.2 (811
+972)
2.6
(653)
18 (10, 25) 0.6 (0.3, 0.8)
Hospital-diagnosed
pneumococcal
pneumonia
Year one 0.27 (49+25) 0.25
(30)
9 (-38, 41) 0.02 (-0.08,
0.13)
Years 2–3 0.18 (56
+42)
0.05
(13)
70 (49, 84) 0.12 (0.08,
0.17)
Empyema Year one 0.02 (2+3) 0.01 (1) 55 (-180, 98) 0.01 (-0.01,
0.03)
Years 2–3 0.01 (2+2) 0 (0) 100 (-240,
100)
0.01 (0, 0.01)
1 Follow-up 136 174+139 820 person-years, age 7–48 months, born Jan’01-May’03.
2Follow-up 273 352+281 012 person-years, age 19–71 months, born Jan’01-May’03 or Jan’03-May’05.
3 Follow-up 122 331 person-years, age 7–48 months, born Jan’08-May’10.
4 Follow-up 246 773 person-years, age 19–71 months, born Jan’08-May’10.
doi:10.1371/journal.pone.0172690.t003
Impact of pneumococcal conjugate vaccine on pneumonia
PLOS ONE | DOI:10.1371/journal.pone.0172690 March 1, 2017 10 / 14
Mycoplasma pneumoniae in 2011 to 2012, and Bordetella pertussis in 2003 to 2004. These
were not closely associated with peaks in pneumonia in calendar years 2001, 2005, and 2007.
The absence of influenza in calendar years 2004 and 2010 was associated with a low pneumo-
nia incidence only in 2004. The yearly fluctuation was lower when epidemic years, rather than
calendar years were evaluated (Fig 4, S2 Fig).
Our study was a nation-wide population-based study, including all hospitals treating pedi-
atric patients in Finland. Through register-linkage and the use of personal identity code, which
is assigned to each resident in Finland and is unique and permanent, allowed close to complete
data collection.
However, as any observational study, also ours is prone to bias due to secular trends and
changes in diagnostic, coding, and treatment practices. Two reference cohorts were selected to
reduce the effect of short-term secular trends and enabled calculation of robust baseline rates.
Pediatric hospital outpatient visits have increased from years 2003–2007 to years 2010–2013
by 10.5% (from 380 to 420 visits per 1000 children under 15 years of age, www.sotkanet.fi). On
the other hand, the corresponding inpatient admissions have decreased from 106 admissions
to 96 admissions per 1000 children by 2013. Thus, the net change for all hospital visits and
admissions combined have increased from 486 to 516, i.e. increase of 6.2%. The increasing
trend prior to the vaccine introduction was also evident for any hospital-diagnosed pneumo-
nia. Since we did not use any adjustment for this trend, our estimates are conservative.
We compared the vaccine-eligible population with a high vaccination coverage (93%), but
not 100%, and some subjects (estimated below 2%) in the unvaccinated reference population
had actually received pneumococcal vaccine. Thus, our estimate for the total impact is an
underestimate of the true vaccine effect. On the other hand, the target cohort for the indirect
impact assessment had probably more commonly received a pneumococcal vaccine (estimated
less than 2% for birth cohort 2008 and less than 10% for birth cohort 2009 and 1-5/2010) than
the corresponding reference cohorts. However, as there was no impact seen in 2011, but only
in 2012 to 2013, it is more probably due to the NVP indirect impact than direct impact of the
vaccinations in older children.
We were not able to collect data on the etiology on the pneumonia episodes. First, those
data are not in the registers (except for bacteremic cases), and secondly, routine microbiolog-
ical diagnostics, like blood cultures, lack sensitivity and they do not very often yield a specific
etiology. Finally, the microbiological assays also suffer from poor specificity, like urine antigen
assays [31], or from poor feasibility, like lung taps. Therefore, nearly all pneumonia cases are
treated empirically, which is also reflected in the non-specific pneumonia codes found in the
data (Table 1). We included all ICD-10 codes for pneumonia, also those for viral pneumonia,
to reduce any potential bias due to changes in coding practices within the pneumonia
diagnoses.
Furthermore, we relied upon register-based diagnoses and no formal radiological evalua-
tion was performed. However, based on FinIP trial data, roughly 90% of pediatric pneumonia
patients in Finland have a chest X-ray available [8] taken on clinical indications; two thirds of
the HTPP episodes were confirmed positive in retrospective radiological evaluation.
Finally, although we collected hospital outpatient pneumonia visits, we did not have data
on pneumonia diagnoses at the public or private ambulatory care outside hospitals. Therefore,
our data represents more severe cases of pneumonia requiring hospital referral.
To our knowledge, this is the first nation-wide population-based impact study to document
the direct and indirect effects of routine PCV10 vaccination among vaccine-eligible and
unvaccinated children. Surveillance data in the coming years will shed more light on the full
potential of PCV10 in reducing pneumonia and other pneumococcal disease in the unvacci-
nated population.
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